XFOR
- X4 Pharmaceuticals, Inc.
()
Overview
Company Summary
X4 Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development of novel drugs to improve the lives of patients with rare diseases. The company specializes in the area of chemokine biology, which involves targeting chemokine receptors and pathways within the immune system to develop therapeutics.
X4 Pharmaceuticals is dedicated to addressing unmet medical needs by leveraging their expertise in chemokine biology and drug development. They have developed a proprietary platform called X4P that enables the discovery and development of small-molecule drug candidates.
One of their lead drug candidates is mavorixafor (X4P-001), which is currently being investigated for multiple indications. Mavorixafor is designed to selectively block the CXCR4 receptor, which plays a crucial role in immune cell trafficking and inflammatory responses. By targeting this receptor, X4 Pharmaceuticals aims to treat diseases where the CXCR4 pathway is dysregulated, such as certain rare genetic disorders and cancer.
Additionally, X4 Pharmaceuticals is actively engaged in preclinical research to identify other potential drug candidates that can modulate chemokine receptors and pathways for the treatment of severe diseases.
Overall, X4 Pharmaceuticals is committed to advancing innovative therapies that have the potential to make a significant impact on the lives of patients with rare diseases who currently have limited treatment options.